Announcements Trials
Browse Landscape

Status

Completed 335Recruiting 99Unknown 85Terminated 82Active not recruiting 52Withdrawn 30Not yet recruiting 25Enrolling by invitation 4Suspended 3No longer available 3Available 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Neoplasms 14Carcinoma, Non-Small-Cell Lung 8Sarcoma 6Prostatic Neoplasms 6Pancreatic Neoplasms 6Neuroblastoma 6Multiple Myeloma 6Recurrence 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Melanoma 5Ovarian Neoplasms 4Leukemia, Myeloid, Acute 4Glioblastoma 4Breast Neoplasms 4Stomach Neoplasms 3Small Cell Lung Carcinoma 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Hematologic Neoplasms 3Head and Neck Neoplasms 3Urinary Bladder Neoplasms 2Primary Myelofibrosis 2Pheochromocytoma 2Osteosarcoma 2Non-Muscle Invasive Bladder Neoplasms 2Neuroectodermal Tumors, Primitive 2Neoplasm Metastasis 2Myelodysplastic Syndromes 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Non-Hodgkin 2

Interventions

ensartinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Available × Carcinoma × Clear all
NCT04146571 2022-10-20

Expanded Access to Ensartinib for Participants With ALK+ NSCLC

Xcovery Holdings, Inc.

Available
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡